Literature DB >> 17229984

Regulation of cGMP synthesis in cultured podocytes by vasoactive hormones.

B Lewko1, M Gołos, E Latawiec, S Angielski, J Stepinski.   

Abstract

The podocytes are highly differentiated cells playing a key role in glomerular filtration. Vasoactive factors including angiotensin II (Ang II) and cyclic guanosine 5' monophosphate (cGMP) are synthesized by these cells upon stimulation as well as in the basal state. In this study we have tested whether angiotensin II affects the total synthesis of cGMP in primary culture of rat podocytes. The cells were stimulated with atrial natriuretic peptide (ANP) and/or a nitric oxide (NO) donor, S-nitroso-N-acetyl penicillamine (SNAP), in the absence or presence of Ang II. The cGMP synthesis was determined by radioimmunoassay (RIA). ANP or SNAP alone increased the cGMP synthesis in podocytes although the effects were not additive unless Ang II was present in the medium. Ang II suppressed the ANP-dependent cGMP synthesis whereas SNAP-dependent cGMP production remained unaffected. These effects were prevented by a non-specific antagonist of Ang II receptors (AT), saralasin. Adversely, PD123319, a specific inhibitor of AT2 receptors, augmented inhibition of ANP-dependent and enhanced the NO-dependent cGMP production. Probenecid, an inhibitor of cGMP extrusion from the cells, suppressed the cGMP generation by both ANP and SNAP. We conclude that cGMP synthesis in cultured podocytes is modulated by angiotensin II and that two adversely acting receptors, AT1 and AT2 are involved in this effect. Additionally, production of cGMP might be intrinsically inhibited by cGMP accumulating inside the cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17229984

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  8 in total

Review 1.  Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy.

Authors:  Peng Hu; Qiang Xuan; Bo Hu; Ling Lu; Yuan Han Qin
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

2.  Natriuretic Peptide Receptor Guanylyl Cyclase-A in Podocytes is Renoprotective but Dispensable for Physiologic Renal Function.

Authors:  Janina Staffel; Daniela Valletta; Anna Federlein; Katharina Ehm; Regine Volkmann; Andrea M Füchsl; Ralph Witzgall; Michaela Kuhn; Frank Schweda
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

Review 3.  A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Pflugers Arch       Date:  2017-06-08       Impact factor: 3.657

4.  Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.

Authors:  Gentzon Hall; Janelle Rowell; Federica Farinelli; Rasheed A Gbadegesin; Peter Lavin; Guanghong Wu; Alison Homstad; Andrew Malone; Thomas Lindsey; Ruiji Jiang; Robert Spurney; Gordon F Tomaselli; David A Kass; Michelle P Winn
Journal:  Am J Physiol Renal Physiol       Date:  2014-04-16

5.  Dexamethasone-dependent modulation of cyclic GMP synthesis in podocytes.

Authors:  Barbara Lewko; Anna Waszkiewicz; Anna Maryn; Magdalena Gołos; Elżbieta Latawiec; Agnieszka Daca; Jacek M Witkowski; Stefan Angielski; Jan Stępiński
Journal:  Mol Cell Biochem       Date:  2015-08-14       Impact factor: 3.396

6.  High glucose induces podocyte epithelial‑to‑mesenchymal transition by demethylation‑mediated enhancement of MMP9 expression.

Authors:  Li Ling; Libo Chen; Changning Zhang; Shuyan Gui; Haiyan Zhao; Zhengzhang Li
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

7.  Blockade of the natriuretic peptide clearance receptor attenuates proteinuria in a mouse model of focal segmental glomerulosclerosis.

Authors:  Liming Wang; Yuping Tang; Anne F Buckley; Robert F Spurney
Journal:  Physiol Rep       Date:  2021-11

8.  Understanding the mechanisms of proteinuria: therapeutic implications.

Authors:  Jorge E Toblli; P Bevione; F Di Gennaro; L Madalena; G Cao; M Angerosa
Journal:  Int J Nephrol       Date:  2012-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.